NCT06263270 — Cytonics cancer immunotherapy trial
Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee
Registry record
| Registry ID | NCT06263270 ↗ |
|---|---|
| Lead sponsor | Cytonics Corporation |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Completed |
| Indication | Osteoarthritis, Knee, Osteoarthritis |
| Enrollment | 19 participants |
| Start date | 2024-06-01 |
| Primary completion | 2025-03-15 |
| Last registry update | 26 Dec 2025 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06263270), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT06263270?
NCT06263270 (Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee) is registered on ClinicalTrials.gov as Phase 1, sponsored by Cytonics Corporation.
Is NCT06263270 recruiting?
As of the 2025-12-26 registry update, NCT06263270 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06263270?
The lead sponsor is Cytonics Corporation.
What condition does NCT06263270 study?
The registered conditions are Osteoarthritis, Knee, Osteoarthritis. Primary completion is listed as 2025-03-15.
Are results available for NCT06263270?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06263270.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.